Careful evaluation of peripheral blood for the presence of circulating plasma cells by morphologic assessment or by flow cytometric analysis is an essential component of the diagnostic workup in all ...

Multiple myeloma is a type of blood cancer that begins in plasma cells found in the bone marrow. About 20% of patients have a genetic change called t (4;14), which makes the NSD2 gene highly active.

So multiple myeloma cells, they grow in the bone marrow. So our main way of detecting plasma cells, myeloma cells or even performing MRD testing remains doing bone marrow biopsies.

The risk of a person progressing from MGUS to myeloma, a cancer of the plasma cells, is 1% per year. In myeloma, a type of white blood cell found in the bone marrow builds up, creating tumors ...

—Arcellx’s BCMA-targeting cell therapy, anito-cel, posted Phase 2 results in multiple myeloma that analysts say are comparable to Carvykti from partners Legend Biotech and Johnson & Johnson.

Multiple myeloma is a relatively rare blood cancer that affects plasma cells, which are white blood cells and part of your immune system. Plasma cells (also known as B-cells) make antibodies.

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma Results At the data-cutoff date, 232 patients had received talquetamab (102 intravenously and 130 subcutaneously).

Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell therapy targeting the “enigmatic” GPRC5D antigen which generated remissions in 70.6% of patients ...